River 2 Renal Corp.
- Address
- 7550 Purple Sage
Sponsor Overview
Specializations
Hepatorenal syndrome and acute kidney injury
River 2 Renal Corp. is active in research for hepatorenal syndrome-associated acute kidney injury, with a focus on patients experiencing severe renal dysfunction in the setting of advanced liver disease. Its clinical portfolio includes evaluation of therapies aimed at improving kidney recovery and reducing dependence on renal replacement therapy.
- Hepatorenal syndrome
- Acute kidney injury
- Renal replacement therapy
The sponsor’s work in this area centers on outcomes tied to serum creatinine improvement and restoration of renal function in patients with severe cirrhosis-related kidney impairment.
Cardiac surgery-associated acute kidney injury
The company also funds studies in cardiac surgery-associated acute kidney injury, targeting individuals at elevated risk after procedures such as coronary artery bypass grafting, valve surgery, and aortic surgery. This research addresses kidney injury linked to cardiopulmonary bypass and perioperative renal stress.
- Coronary artery bypass grafting
- Valve surgery
- Aortic surgery
Clinical interest extends to preventing postoperative acute kidney injury in patients with additional risk factors for renal complications after major cardiovascular operations.
Renal protection and kidney function preservation
River 2 Renal Corp. has a clear therapeutic focus on preserving kidney function in settings where renal injury is likely to progress. Its research spans both treatment and prevention strategies for AKI, with attention to clinical outcomes that reflect sustained renal recovery.
- Kidney function preservation
- Renal recovery
- Acute kidney injury prevention
The sponsor’s current activity includes work in populations where renal perfusion and kidney resilience are compromised by systemic illness or surgical stress.
Vasopressor-based renal support
Another area of interest is the use of vasopressor-based therapy in combination with agents intended to support renal perfusion and improve kidney-related outcomes. This includes research in patients with circulatory instability and severe renal impairment.
- Terlipressin
- Renal perfusion
- Circulatory support
The sponsor’s clinical work links renal outcomes with hemodynamic management in both liver-related and perioperative kidney injury settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Tolerability, and Efficacy of Relaxin Agonist R2R01 with Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury |  Germany Italy | Not Recruiting |
| Phase 2 Randomized Study of R2R01 for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury in High-Risk Patients | Germany Italy | Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 31 sites across their trial portfolio.
Therapeutic Focus
- 1.Pathological Conditions, Signs and Symptoms2 trials91 other sponsors
Partnered Research Centres
31 centres- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Via Venezia 16, 15121 Alessandria
- Address
- Via Ferdinando Magellano 1, 10128 Turin
- Address
- Via Potito Petrone, 85100 Potenza
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
Want to get in touch with this sponsor?
Send a question and we'll pass it on to River 2 Renal Corp..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.